In 262 adults with type 2 diabetes on metformin, once-weekly zenagamtide 0·4–40 mg lowered HbA1c at 36 weeks vs placebo, by 0·77% (0·4 mg) to 1·56% (40 mg) points. Adverse events were mostly mild-to-moderate gastrointestinal; 8% had serious events.
RCTn = 262
Mora et al. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial